Control of the innate immune response by the mevalonate pathway

Nature Immunology

Volumn 17, Issue 8, 2016, Pages 922-929

  Akula, Murali K ^a,b   Shi, Man ^a   Jiang, Zhaozhao ^c   Foster, Celia E ^c   Miao, David ^a   Li, Annie S ^c   Zhang, Xiaoman ^c   Gavin, Ruth M ^c   Forde, Sorcha D ^c   Germain, Gail ^c   Carpenter, Susan ^c   Rosadini, Charles V ^d   Gritsman, Kira ^e   Chae, Jae Jin ^f   Hampton, Randolph ^g   Silverman, Neal ^c   Gravallese, Ellen M ^c   Kagan, Jonathan C ^d   Fitzgerald, Katherine A ^c   Kastner, Daniel L ^f   Golenbock, Douglas T ^c   Bergo, Martin O ^b   Wang, Donghai ^a,c   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIM2 PROTEIN; CASPASE 11; CRYOPYRIN; CXCL1 CHEMOKINE; ENZYME; GERANYLGERANYL TRANSFERASE I; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B KINASE BETA; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; K RAS PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEVALONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GERANYLGERANYL PYROPHOSPHATE; GERANYLGERANYLTRANSFERASE TYPE-I; ISOPRENOID PHOSPHATE; MEVALONATE KINASE; PHOSPHOTRANSFERASE; TRANSFERASE;

ANIMAL CELL; ARTICLE; CATALYSIS; CHEMICAL REACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GERANYLGERANYLATION; HUMAN; HUMAN CELL; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELLS, CULTURED; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; MICE, INBRED C57BL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYISOPRENYL PHOSPHATES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84976313489     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3487     Document Type: Article

References (46)

1. Goldstein J.L., & Brown M.S. Regulation of the mevalonate pathway. Nature 343, 425-430 (1990).
2. Frenkel J., et al. Mevalonate kinase deficiency and Dutch type periodic fever. Clin. Exp. Rheumatol. 18, 525-532 (2000).
3. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
4. Martinon F., Mayor A., & Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
5. Kastner D.L., Aksentijevich I., & Goldbach-Mansky R. Autoinflammatory disease reloaded: A clinical perspective. Cell 140, 784-790 (2010).
6. Xu H., et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513, 237-241 (2014).
7. Beurel E., Michalek S.M., & Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 31, 24-31 (2010).
8. Hazeki K., Nigorikawa K., & Hazeki O. Role of phosphoinositide 3-kinase in innate immunity. Biol. Pharm. Bull. 30, 1617-1623 (2007).
9. Androulidaki A., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31, 220-231 (2009).
10. Martin M., Rehani K., Jope R.S., & Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784 (2005).
11. Weichhart T., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29, 565-577 (2008).
12. Weichhart T., & Säemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 67 (suppl. 3), iii70-iii74 (2008).
13. Ohtani M., et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112, 635-643 (2008).
14. Fritsch R., et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050-1063 (2013).
15. Zhang F.L., & Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (1996).
16. Khan O.M., et al. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J. Clin. Invest. 121, 628-639 (2011).
17. Takeuchi O., & Akira S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
18. Aksoy E., et al. The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat. Immunol. 13, 1045-1054 (2012).
19. Fukao T., et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875-881 (2002).
20. Luyendyk J.P., et al. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 180, 4218-4226 (2008).
21. Wang H., Brown J., & Martin M. Glycogen synthase kinase 3: A point of convergence for the host inflammatory response. Cytokine 53, 130-140 (2011).
22. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31, 675-704 (2013).
23. Lucas C.L., et al. Dominant-Activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88-97 (2014).
24. Gupta S., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
25. Maurer-Stroh S., et al. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput. Biol. 3, e66 (2007).
26. Sebti S.M., & Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-To-bedside translational studies. Oncogene 19, 6584-6593 (2000).
27. Kinsella B.T., Erdman R.A., & Maltese W.A. Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-Terminal amino acid. Proc. Natl. Acad. Sci. USA 88, 8934-8938 (1991).
28. Galeotti C., et al. Efficacy of interleukin-1-Targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 51, 1855-1859 (2012).
29. Rathinam V.A., et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 150, 606-619 (2012).
30. Papin S., et al. The tumor necrosis factor alpha-dependent activation of the human mediterranean fever (MEFV) promoter is mediated by A synergistic interaction between C/EBP beta and NF kappaB p65. J. Biol. Chem. 278, 48839-48847 (2003).
31. Ni M., et al. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc. Natl. Acad. Sci. USA 109, 267-272 (2012).
32. Sarkar S.N., et al. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat. Struct. Mol. Biol. 11, 1060-1067 (2004).
33. Wang H., et al. IFN-beta production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-beta. J. Immunol. 181, 6797-6802 (2008).
34. Wang J.T., et al. Glycogen synthase kinase 3 negatively regulates IFN regulatory factor 3 transactivation through phosphorylation at its linker region. Innate Immun. 20, 78-87 (2014).
35. Hrincius E.R., et al. Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production. Cell. Microbiol. 13, 1907-1919 (2011).
36. Castellano E., & Downward J. Role of RAS in the regulation of PI 3-kinase. Curr. Top. Microbiol. Immunol. 346, 143-169 (2010).
37. Berndt N., Hamilton A.D., & Sebti S.M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791 (2011).
38. James G.L., Goldstein J.L., & Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270, 6221-6226 (1995).
39. Lerner E.C., Qian Y., Hamilton A.D., & Sebti S.M. Disruption of oncogenic K-Ras4B processing and signaling by A potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270, 26770-26773 (1995).
40. Rowell C.A., Kowalczyk J.J., Lewis M.D., & Garcia A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272, 14093-14097 (1997).
41. Engelman J.A., Luo J., & Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
42. Sjogren A.K., et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J. Clin. Invest. 117, 1294-1304 (2007).
43. Jou S.T., et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591 (2002).
44. Mariathasan S., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218 (2004).
45. Roberts Z.J., et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J. Exp. Med. 204, 1559-1569 (2007).
46. Bonham K.S., et al. A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. Cell 156, 705-716 (2014).